Here’s a roundup of the latest news coverage from Drug Topics®.
Pharmacy Groups Back Washington State Court Decision on ‘Unsustainable’ CMS Reimbursement Law
WSPA, NPCA, and NACDS fully support the court decision requiring CMS to reconsider the below-cost reimbursement plan.
Johnson & Johnson Recalls 5 Aerosol Sunscreen Brands with Benzene Traces
The consumer products giant voluntarily recalled 4 NEUTROGENA® and 1 AVEENO® spray sunscreen products July 14 after internal testing found low levels of benzene, a carcinogen, in some product samples.
Stanford Study Shows Memory T Cells Are Active Defense Against Severe COVID-19
Stanford study indicates that immune cells respond better to COVID-19 infection when patients have already been exposed to other, less deadly coronaviruses.
Novel Antifungal Treatment Approved for Vaginal Candidiasis
On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the FDA for vulvovaginal candidiasis in adult women and girls who have begun menstruating.
FDA Grants Priority Review to Tezepelumab for Severe Asthma
Tezepelumab is the first biologic medication to show a reduction in severe asthma symptoms.
Rare Cases of Guillain-Barré Syndrome Reported in Janssen COVID-19 Vaccine
Johnson & Johnson released a statement providing more information on the risks and benefits of its single-shot COVID-19 vaccine.
FDA OKs Finerenone for Chronic Kidney Disease Associated With Type 2 Diabetes
A new medication called finerenone (Kerendia; Bayer) has been approved for the treatment of kidney disease and type 2 diabetes.